VKTX - Viking Therapeutics, Inc.
About Viking Therapeutics, Inc. (https://www.vikingtherapeutics.com)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Brian Lian | President, Chief Executive Officer & Director | 1966 | $1,045,000 USD |
| Marianne Mancini | Chief Operating Officer | 1965 | $765,000 USD |
| Gregory S. Zante | Chief Financial Officer | 1971 | $738,000 USD |
| Michael Morneau | Vice President of Finance & Administration | 1965 | $375,333 USD |
| Geoffrey E. Barker | Chief Development Officer | – | – |
| Katherine Mercier | Vice President of Quality and Compliance | – | – |
| Kenneth Herman | Senior Vice President of Commercial, Marketing & Sales | – | – |
| Neil Aubuchon | Chief Commercial Officer | 1971 | – |
| Nils U. Olsson | Senior Vice President of Technical Operations | – | – |